Xeris Biopharma (NASDAQ:XERS) Announces Quarterly Earnings Results

Xeris Biopharma (NASDAQ:XERS) released its quarterly earnings data on Monday. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03, reports. The business had revenue of $85.81 million during the quarter, compared to analysts’ expectations of $86.00 million.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Financial self-sustainability achieved — Xeris reported full-year net income and ~$59.4M adjusted EBITDA in 2025 and guided 2026 revenue of $375–$390M while expecting to remain adjusted EBITDA positive.
• Recorlev is the primary growth engine, ending 2025 at ~700 patients (nearly double year‑over‑year) with FY revenue of $139.3M, and the company nearly doubled its commercial team in January to accelerate adoption with impacts expected notably in H2 2026.
• Xeris filed a patent infringement lawsuit against two ANDA filers to defend Recorlev and points to four Orange Book‑listed patents through March 2040 and orphan exclusivity to end of 2028, but litigation timelines are uncertain and could create a multi‑year overhang.
• The pipeline priority XP‑8121 (once‑weekly subcutaneous levothyroxine) is planned to start Phase 3 in H2 2026, targets an estimated 3–5M patients with absorption issues, and is modeled for potential peak sales of $1–$3B, with R&D budget to increase by about $25M to support the program.
• The commercial portfolio is durable — Gvoke and Keveyis delivered steady contributions, gross margin improved to ~85% for 2025 (87% in Q4), and management expects further margin improvement and continued operating leverage despite planned SG&A investments (~$45M) to scale Recorlev.

Xeris Biopharma Trading Down 1.6%

XERS traded down $0.10 during midday trading on Monday, hitting $6.02. 5,043,164 shares of the company traded hands, compared to its average volume of 2,062,694. The business has a 50 day simple moving average of $7.23 and a two-hundred day simple moving average of $7.64. Xeris Biopharma has a 52-week low of $3.59 and a 52-week high of $10.08. The company has a market capitalization of $998.86 million, a price-to-earnings ratio of -60.19 and a beta of 0.52.

Insider Activity

In other news, Director John Johnson sold 135,400 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.22, for a total value of $977,588.00. Following the transaction, the director owned 698,083 shares in the company, valued at $5,040,159.26. This trade represents a 16.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kevin Mcculloch sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $8.00, for a total value of $120,000.00. Following the sale, the insider owned 1,685,426 shares of the company’s stock, valued at $13,483,408. The trade was a 0.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 223,641 shares of company stock worth $1,628,285. Company insiders own 6.47% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in Xeris Biopharma by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock valued at $33,571,000 after purchasing an additional 135,815 shares during the last quarter. State Street Corp raised its position in shares of Xeris Biopharma by 10.1% during the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock valued at $32,318,000 after buying an additional 378,595 shares during the period. Qube Research & Technologies Ltd raised its position in shares of Xeris Biopharma by 6.0% during the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock valued at $26,657,000 after buying an additional 185,063 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after acquiring an additional 1,199,435 shares during the last quarter. Finally, Millennium Management LLC grew its position in Xeris Biopharma by 19.0% in the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after acquiring an additional 369,420 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analysts Set New Price Targets

XERS has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a research report on Monday. Piper Sandler boosted their price target on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Barclays started coverage on shares of Xeris Biopharma in a report on Monday, December 8th. They set an “overweight” rating and a $9.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, January 21st. Finally, Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.08.

Trending Headlines about Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q4 results beat on EPS and management raised FY‑2026 revenue guidance — Xeris reported $0.06 EPS vs. $0.03 consensus and issued revenue guidance of $375.0M–$390.0M (above the $370.3M consensus), a constructive top‑line outlook that can support valuation and growth expectations. Press Release
• Positive Sentiment: HC Wainwright reaffirmed a Buy and set a $10 price target — analyst backing and a mid‑double‑digit upside target (about 66% from current levels) provide a bullish catalyst if sentiment improves. HC Wainwright Reaffirmation
• Neutral Sentiment: Conference call / transcripts available — management commentary and the Q&A will be key for clarity on margin drivers, growth cadence, and timing of any product/lifecycle initiatives. Earnings Call Transcript
• Neutral Sentiment: Press coverage and analyst notes summarize the results — most outlets note the EPS beat but highlight that reported revenue of $85.81M was just shy of the $86.0M estimate (a mixed signal). Zacks Coverage
• Negative Sentiment: Recurlev/Recorlev exclusivity and valuation risk — recent coverage highlights Xeris’ efforts to defend Recorlev exclusivity; litigation/regulatory outcomes are uncertain and could materially affect future revenue. Yahoo Valuation / Exclusivity Article
• Negative Sentiment: Guidance omitted EPS detail and revenue miss vs. quarterly estimate — while revenue guidance was raised, management didn’t provide clear EPS guidance in the release and quarter revenue was a touch below expectations, leaving short‑term profitability visibility limited. No link

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.